CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Continuous support for cancer research from the public as well as private sector
4.1.2. Increasing demand for personalised medicine
4.1.3. Growth in the number of pharmaceutical R&D activities
4.1.4. Government initiatives and funding for promoting patient-derived xenograft models
4.2. Market Restraints & Challenges
4.2.1. Stringent guidelines for the use of animal models in cancer research
4.2.2. Limitations of PDX models
4.3. Market Opportunities
4.3.1. Increasing demand for humanised PDX models
4.3.2. Emerging economies
CHAPTER 5. GLOBAL PATIENT DERIVED XENOGRAFT MODELS MARKET –
BY TUMOR TYPE
5.1. Introduction
5.2. Respiratory tumour models
5.3. Gynaecological tumour models
5.4. Gastrointestinal tumour models
5.5. Urological tumour models
5.6. Haematological tumour models
5.7. Other tumour models
CHAPTER 6. GLOBAL PATIENT DERIVED XENOGRAFT MODELS MARKET –
BY TYPE
6.1. Introduction
6.2. Mice models
6.3. Rat models
CHAPTER 7. GLOBAL PATIENT DERIVED XENOGRAFT MODELS MARKET –
BY APPLICATION
7.1. Introduction
7.2. Preclinical drug development and basic cancer research
7.3. Biomarker analysis
CHAPTER 8. GLOBAL PATIENT DERIVED XENOGRAFT MODELS MARKET - BY
END USER
8.1. Introduction
8.2. Academic & research institutions
8.3. Contract research organisations
8.4. Pharmaceutical & biotechnology companies
CHAPTER 9. GLOBAL PATIENT DERIVED XENOGRAFT MODELS MARKET - BY
GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. APAC
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10. GLOBAL PATIENT DERIVED XENOGRAFT MODELS MARKET -
COMPANY PROFILES
10.1. Bioduro, LLC
10.2. Champions Oncology Inc.
10.3. Charles River Laboratories International Inc.
10.4. Crown Bioscience Inc.
10.5. Epo Berlin-Buch Gmbh
10.6. Hera Biolabs.
10.7. Horizon Discovery Group Plc
10.8. Oncodesign.
10.9. Pharmatest Services Ltd.
10.10. Shanghai Lide Biotech Co. Ltd.
10.11. The Jackson Laboratory.
10.12. Urolead
10.13. WuXiAppTec Group.
10.14. Xenopat
10.15. Sigma-Aldrich Corporation.
CHAPTER 11. GLOBAL PATIENT DERIVED XENOGRAFT MODELS MARKET –
COMPETITIVE LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12. MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13. APPENDIX
13.1. List of Tables
13.2. List of Figures
